SELLAS Life Sciences (SLS) shares jumped outside regular hours after the company's third-quarter update on Thursday, November 12, 2026, said topline primary-endpoint results from its Phase 3 REGAL trial are now due
this month.
TokenPost reported a
20% gain in extended trading Thursday, and
Yahoo Finance had the stock up
around 15% early Friday. SLS closed Thursday's regular session at
$8.03; a delayed
Cboe quote showed
$9.17 early Friday, about 14% higher.
From "This Quarter" to "This Month"
On October 28, SELLAS said REGAL had reached its pre-specified 80th event (deaths), which triggers database lock, unblinding and the final analysis. At that point it only promised results "this quarter." The Q3 release tightened that to November. Key points from the company:
REGAL tests galinpepimut-S (GPS), a WT1-targeted immunotherapy, as maintenance for AML patients in second complete remission. The primary endpoint is overall survival (ClinicalTrials.gov NCT04229979).
Cash and equivalents were $134.7 million at September 30.
Q3 net loss was $10.1 million, or $0.05 per share; TokenPost said the per-share loss was in line with estimates.
Separately, preliminary topline data from a Phase 2 trial of SLS009 (tambiciclib) in newly diagnosed AML, with 40 patients enrolled, is expected in Q4.The company gave no exact date for the REGAL readout.
What a 336 IV30 Actually Says
Cboe's 30-day implied volatility index for SLS closed Thursday near 336. That is not a normal reading for a stock. It means the options market expects a very large move once the data comes out, in either direction. Straddles at the $8 strike, from Thursday's closing Cboe quotes with SLS at $8.03:
| Expiry | Call bid/ask | Put bid/ask | Straddle (mid) | % of stock |
| Fri Nov 13 | $0.30 / $0.55 | $0.20 / $0.60 | ~$0.83 | ~10% |
| Fri Nov 20 | $0.95 / $1.60 | $1.00 / $1.25 | ~$2.40 | ~30% |
| Fri Nov 27 | $0.95 / $2.60 | $1.30 / $2.50 | ~$3.68 | ~46% | Two cautions. First, these quotes are from before the after-hours jump, so the stock now sits closer to the call side. Second, the bid/ask spreads are wide. On the Nov 27 call, the ask is almost three times the bid, so the midpoint is only a rough guide, and getting filled near it is not guaranteed. The price jump from Nov 20 (~30%) to Nov 27 (~46%) is how the market spreads out its guess about timing. Since SELLAS only said "this month," the later expiries are the ones most likely to include the readout. Thursday's Flow Leaned Toward Calls, With Big Put Positions UnderneathCboe counted about 11,100 calls and 6,000 puts traded on Thursday. The most active lines: | Contract | Volume | Open interest (start of day) |
| Nov 13 $12.50 call | ~1,172 | ~1,939 |
| Dec 18 $10 call | ~1,172 | ~1,776 |
| Jan 2027 $2 put | ~1,163 | ~8,946 |
| Nov 13 $9 call | ~1,140 | ~3,399 |
| Jan 2027 $7 put | ~1,093 | ~12,988 |
The January $7 put had nearly 13,000 contracts open and was quoted at $3.30 / $4.00, with the stock at $8.03. Paying that much for a put struck below the stock price means the market sees a real chance of a sharp drop. Volume numbers don't show who bought or sold, or whether these trades were hedges.
Trading Around a Single-Readout Biotech
Educational points only:
The data is the whole story. A positive overall-survival result could support a BLA filing; a miss on a single pivotal trial can take a big piece of a clinical-stage company's value away. Options are priced for that split, which is why premiums are so high.
Long premium needs a big move. A buyer of the Nov 27 straddle at the midpoint needed SLS to move roughly 46% by expiration just to break even. That's a high bar, even for a binary event.
Short premium has gap risk. Selling options here collects a lot of premium, but the stock can gap far past any strike overnight. Defined-risk spreads limit the worst case; naked short options don't.
IV crush comes after the news. Once results are public, implied volatility usually falls sharply. Options can lose value even when the stock moves in the expected direction, if the move is smaller than what was priced in.
Timing risk. With no exact date, contracts that expire before the announcement lose most of their event premium. Some may expire worthless before the news arrives.See our implied volatility explainer and the OCC options disclosure document for the basics.
Sources
SELLAS Life Sciences: Third Quarter 2026 Financial Results and Corporate Update
SELLAS Life Sciences: Reaches 80th Event in Phase 3 REGAL Trial
TokenPost: SELLAS Shares Rise 20% as It Expects Leukemia Trial Results This Month
Yahoo Finance: Futures Edge Lower As NVDA Fallout Unsettles Tech Stocks
ClinicalTrials.gov: NCT04229979 (REGAL)
Cboe: SLS delayed quotes and options*By the OptionsPilot Editorial Team. Published November 13, 2026, 4:17 AM PT. This article is for education only and is not investment advice. Options involve risk and are not suitable for all investors.*